A study of the comparative in vitro activity of telithromycin, a new ketolide, against 155 aerobic and 171 anaerobic antral sinus puncture isolates showed it to be active against a broad range of sinus pathogens. All pneumococci, including erythromycin-resistant strains, were susceptible to telithromycin at <0.5 g/ml; all Haemophilus influenzae and Eikenella corrodens strains were inhibited by <4 g of telithromycin/ml; all Moraxella spp. and beta-lactamase-producing Prevotella species strains were inhibited by <0.25 and 0.5 g of telithromycin/ml, respectively. Among all anaerobes tested, 94% (160 of 171 strains) were susceptible to <4 g of telithromycin/ml; however, 8 of 17 (47%) Fusobacterium strains, 2 Veillonella strains, and 1 Peptostreptococcus micros strain required >4 g of telithromycin/ml for inhibition. Telithromycin may offer a therapeutic alternative for sinus infections, including those due to erythromycin-resistant pneumococci.
Bacterial sinusitis affects ca. 30 million Americans annually (22, 25) . Macrolides have commonly been used to treat acute bacterial maxillary sinusitis with targeted activity against pneumococci, Haemophilus spp., and Moraxella catarrhalis; however, there is increasing resistance to these and other antimicrobials (14, 15, 18, 24) , with sinus isolates being possibly more resistant than their general respiratory counterparts (6) . Anaerobic bacteria, which are important pathogens in chronic sinusitis (11, 17) , are often ignored by clinicians and their in vitro susceptibilities are infrequently reported by most respiratory or sinus studies (1, 3, 8) .
Telithromycin is a new ketolide agent with a broad spectrum of activity, including activity against macrolide-resistant pathogens and many anaerobic bacteria (1, 7, 12, 16) . In order to evaluate the potential efficacy of telithromycin in the therapy of sinusitis, we determined its comparative in vitro activity against 326 recent aerobic and anaerobic clinical isolates from patients with sinusitis.
Strains were isolated from antral puncture specimens obtained from adult patients between 1994 and 2002 and were identified by standard criteria (19, 23 (20, 21) . Brucella agar supplemented with hemin, vitamin K 1 , and 5% laked sheep blood was the basal medium used for anaerobic species. The broth microdilution method and an inoculum of ca. 5 ϫ 10 4 CFU per well was used for aerobes (21) , and the agar dilution method with an inoculum of 10 5 CFU per spot was used for anaerobes (20) .
(This work was presented in part at the 40th Annual Meeting of the Infectious Diseases Society of America, Chicago, Ill., 24 to 27 October 2002.)
The proposed preliminary breakpoints for telithromycin were as follows: for pneumococci, streptococci, and staphylococci, Յ1 g/ml is considered susceptible, 2 g/ml is considered intermediate, and Ն4 g/ml is considered resistant; for Haemophilus influenzae, Յ2 g/ml is considered susceptible, 4 g/ml is considered intermediate, and Ն8 g/ml is considered a n ϭ number of isolates tested. b Includes H influenzae (n ϭ 2) and H. paraphrophilus (n ϭ 3). c Includes Eschericiha coli (n ϭ 6), Citrobacter koseri (n ϭ 2), Enterobacter aerogenes (n ϭ 2), Enterobacter cloacae (n ϭ 3), Hafnia alvei (n ϭ 1), Klebsiella oxytoca (n ϭ 3), Klebsiella pneumoniae (n ϭ 1), Pantoea agglomerans (n ϭ 1), Proteus mirabilis (n ϭ 1), Serratia liquefaciens, (n ϭ 2), and Serratia marcescens (n ϭ 1).
d Includes Achromobacter xylosoxidans (n ϭ 2), Pseudomonas aeruginosa (n ϭ 9), Acinetobacter baumannii (n ϭ 1), Acinetobacter lwoffi (n ϭ 1), Bordetella bronchiseptica (n ϭ 1), Flavobacterium sp. strain IIb (n ϭ 3), and Stenotrophomonas maltophilia (n ϭ 3).
e Includes F nucleatum (n ϭ 14), F. necrophorum (n ϭ 2), and F. naviforme (n ϭ 1). f Includes P. intermedia (n ϭ 1) and P. melaninogenica (n ϭ 15). g Includes P. bivia (n ϭ 2), P. buccae (n ϭ 8), and P. oris (n ϭ 4). h Includes P. avidum (n ϭ 6), P. granulosum (n ϭ 5), and Propionibacterium spp. (n ϭ 3). 16 Veillonella strains, and 1 Peptostreptococcus micros isolate. Our study did not include any pediatric strains that may be more resistant than adult strains (6, 14) . Although macrolides have been recommended as first-line therapy in sinusitis (11), macrolide resistance among clinical Streptococcus pneumoniae isolates has been reported to range from 11.1% among Canadian isolates collected in 2000 (18) to 20.4% for invasive isolates collected in the United States in 1999 (14) . Telithromycin has previously been noted to be active against erythromycin-resistant pneumococci "irrespective of their mechanism of macrolide resistance" (2, 15) and to "select for resistance less often" than the lower-level macrolides (5). In our study, telithromycin had an MIC at which 90% of the isolates tested are inhibited (MIC 90 ) of 0.03 g/ml against pneumococci that was much more active than the MIC 90 s of erythromycin (4 g/ml), azithromycin (Ͼ32 g/ml), and clarithromycin (2 g/ml). Three pneumococcal sinus isolates were resistant to penicillin, whereas none were resistant to amoxicillin according to newly proposed NCCLS breakpoints. Of 30 isolates, 5 (17%) were resistant to erythromycin, as well as resistant to azithromycin, roxithromycin, and clarithromycin.
These data are in accord with those reported by other investigators (2, 13). Hoban et al. (13) reported telithromycin MIC 90 s of Յ0.12 g/ml for both penicillin-susceptible and -intermediate pneumococci and of 0.25 g/ml for penicillin-resistant strains isolated in Canada in 1997 and 1998. One of our macrolide-resistant isolates was also resistant to all three fluoroquinolones but susceptible to telithromycin. Doern et al. (6) noted that 39% of sinus pneumococcus isolates were resistant to penicillin compared to 26% overall resistance in general isolates and also noted that 10% of the pneumococcus strains were resistant to azithromycin, clarithromycin, and erythromycin, while Thornsberry et al. (24) reported 29% resistance among pneumococcal strains to clarithromycin.
Against Staphylococcus aureus, telithromycin had an MIC 90 of 0.25 g/ml versus erythromycin, azithromycin, and clarithromycin (without the addition of the 14-hydroxy clarithromycin), which each had an MIC 90 Ͼ32 g/ml. In our study, 54% (14 of 26) of Haemophilus influenzae strains were beta-lactamase producers. Telithromycin had an MIC 90 of 4 g/ml compared to MICs of 16 g/ml for clarithromycin, 8 g/ml for azithromycin and erythromycin, and 32 g/ml for roxithromycin. Hoban et al. (13) also noted that telithromycin and clarithromycin had, respectively, MIC 90 s of 4 and 16 g/ml against 1,438 Canadian isolates (obtained from 1997 to 1998) of Haemophilus influenzae. However, these authors noted azithromycin MIC 90 s of 2 g/ml against beta-lactamase-negative strains and 4 g/ml against beta-lactamase-positive strains. We did not observe a similar pattern in our strains, although the number of isolates we tested was much smaller. Thornsberry et al. (24) noted that only 67 and 58% of Haemophilus influenzae strains were amoxicillin and clarithromycin susceptible, respectively. Clinical correlation of these susceptibility results against Haemophilus species has not yet been done.
In agreement with the results of Hoban et al. (13), we also found that telithromycin had an MIC 90 of 0.125 g/ml against Moraxella catarrhalis, which was comparable to those of the macrolides studied. Telithromycin performed well against Eikenella corrodens, with an MIC 90 of 2 g/ml, compared to 16 g/ml for clarithromycin and azithromycin and 32 g/ml for roxithromycin and erythromycin. Levofloxacin also showed good activity against most aerobic sinus isolates, including Eikenella corrodens.
Studies of the anaerobic activity of telithromycin have focused on general and abdominal isolates, with scant information presented regarding respiratory anaerobic isolates (7, 8, 12) . In our study telithromycin was quite active (MIC, Յ4 g/ml) against 94% of the anaerobe strains tested.
Methodological differences and the effect of CO 2 in the atmosphere of incubation on the pH of the medium may account for some of the variability between the studies (4, (8) (9) (10) 12 ), but results were remarkably similar overall. Ednie et al. (8) , who used the Oxyrase method and Wilkins-Chalgren agar without CO 2 , reported a telithromycin MIC 50 of 4 g/ml for nine Fusobacterium nucleatum strains and an MIC 90 of 0.25 g/ml for Prevotella melaninogenica. Edlund et al. (7) reported telithromycin to have an MIC range of 0.016 to 8.0 g/ml against 30 isolates of Fusobacterium nucleatum and of 0.016 to 1.0 g/ml against 30 strains of Propionibacteriumacnes.
Telithromycin had its greatest activity against gram-positive aerobes and gram-positive anaerobes. Some aerobic gram-negative strains, as wells as anaerobic strains of Fusobacterium species and Veillonella species, may be resistant to telithromycin. However, compared to currently available macrolides, it exhibited overall a broader spectrum of activity against sinus pathogens, especially those resistant to erythromycin, and thus merits further evaluation as a therapeutic alternative in sinusitis.
